It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Right-sided colon cancer (RCC) and left-sided colon cancer (LCC) differ in their clinical and molecular features. An investigation of differentially expressed genes (DEGs) between RCC and LCC could contribute to targeted therapy for colon cancer, especially RCC, which has a poor prognosis. Here, we identified HOXB13, which was significantly less expressed in RCC than in LCC and associated with prognosis in RCC, by using 5 datasets from the Gene Expression Omnibus (GEO). Tissue sample analysis showed that HOXB13 was differentially expressed between normal and only RCC tumor tissues. HOXB13 inhibited colon cancer cell proliferation and induced apoptosis both in vitro and in vivo. Furthermore, we found that HOXB13 might be regulated by DNMT3B and suppress C-myc expression to exert antitumor effects via β-catenin/TCF4 signals in RCC. In conclusion, the current study is the first to demonstrate that HOXB13 has a tumor-suppressive effect in RCC. High expression levels of HOXB13 are associated with prolonged overall survival in patients with RCC. The DNMT3B-HOXB13-C-myc signaling axis might be a molecular target for the treatment of RCC.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Zhejiang University, Department of Medical Oncology; Sir Run Run Shaw Hospital; School of Medicine, Hangzhou, PR China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
2 Zhejiang University, Department of Colorectal Surgery; Sir Run Run Shaw Hospital; School of Medicine, Hangzhou, PR China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
3 Zhejiang University, Department of Stomatology; Stomatology Hospital; School of Medicine, Hangzhou, PR China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
4 Suzhou University, Department of Medical Oncology; The Second Affiliated Hospital of Suzhou University; School of Medicine, Suzhou, PR China (GRID:grid.263761.7) (ISNI:0000 0001 0198 0694)
5 Anhui University of Science and Technology, School of Medicine, Huainan, PR China (GRID:grid.440648.a) (ISNI:0000 0001 0477 188X)